The "Molecular Biology for the Non-molecular Biologist Training Course (Apr 20th - Apr 21st, 2026)" training has been added to ResearchAndMarkets.com's offering.Elevate your expertise in molecular ...

At its J.P. Morgan Conference 2026 presentation, Qiagen NV alluded to positive full-year results for 2025 and expressed that ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

DUBLIN-- (BUSINESS WIRE)--January 13, 2026-- The "Biomedical and ICT Convergence Market by Technology, Solution and Region 2025-2030" report has been added to ResearchAndMarkets.com's offering.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and ...

PCR-based techniques have transformed how scientists analyze transcripts’ translational applications in cancer and ...

A landmark study, titled “How error correction affects polymerase chain reaction deduplication: A survey based on unique molecular identifier datasets of short ...

Regeneron Pharmaceuticals, Inc. REGN announced updated data on its investigational gene therapy DB-OTO from the CHORD study. This gene therapy is being evaluated for profound genetic hearing loss due ...

This study provides valuable information on the impact of Lamin A/C knockdown on gene expression using RNA-Seq analysis, as well as on telomere dynamics through live cell imaging. However, the ...

Apple analysts and investors are continuing to track lead times on the new iPhone 17, which could point to how demand there is for the company's latest smartphone. "Since launch, the global lead time ...

Regeneron has posted updated clinical data on DB-OTO, providing more evidence of the gene therapy’s potential to treat a rare genetic form of deafness as it plans for a potential FDA filing later this ...

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's ...